CA2783876C - New conjugates and compositions for immunotherapy and antitumoral treatment - Google Patents

New conjugates and compositions for immunotherapy and antitumoral treatment Download PDF

Info

Publication number
CA2783876C
CA2783876C CA2783876A CA2783876A CA2783876C CA 2783876 C CA2783876 C CA 2783876C CA 2783876 A CA2783876 A CA 2783876A CA 2783876 A CA2783876 A CA 2783876A CA 2783876 C CA2783876 C CA 2783876C
Authority
CA
Canada
Prior art keywords
leu
glu
ser
lys
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2783876A
Other languages
English (en)
French (fr)
Other versions
CA2783876A1 (en
Inventor
Pedro Berraondo Lopez
Jessica Fioravanti
Jose Medina Echeverz
Ignacio Javier Melero Bermejo
Maria Del Carmen Ochoa Nieto
Francisco De Asis Palazon Garcia
Silvia Bulfone-Paus
Erwin Hans Duitman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Proyecto de Biomedicina CIMA SL
Original Assignee
Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed by Forschungszentrum Borstel Leibniz Lungenzentrum FZB, Proyecto de Biomedicina CIMA SL filed Critical Forschungszentrum Borstel Leibniz Lungenzentrum FZB
Publication of CA2783876A1 publication Critical patent/CA2783876A1/en
Application granted granted Critical
Publication of CA2783876C publication Critical patent/CA2783876C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5443IL-15
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2783876A 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and antitumoral treatment Expired - Fee Related CA2783876C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ES201030813 2010-05-27
ESP201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (2)

Publication Number Publication Date
CA2783876A1 CA2783876A1 (en) 2011-06-16
CA2783876C true CA2783876C (en) 2018-04-03

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2783876A Expired - Fee Related CA2783876C (en) 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and antitumoral treatment

Country Status (11)

Country Link
US (1) US8771664B2 (enExample)
EP (1) EP2511294B1 (enExample)
JP (1) JP5784626B2 (enExample)
CN (1) CN102753574B (enExample)
AU (1) AU2010329805B2 (enExample)
BR (1) BR112012013868A8 (enExample)
CA (1) CA2783876C (enExample)
ES (1) ES2463016T3 (enExample)
MX (1) MX2012006691A (enExample)
RU (1) RU2597989C2 (enExample)
WO (1) WO2011070214A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP4032540A1 (en) * 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
WO2015054701A2 (en) * 2013-10-13 2015-04-16 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness & myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15
CA3193936A1 (en) 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
EP3307783B1 (en) * 2015-06-10 2021-01-06 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 조정
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
US11866466B2 (en) 2017-12-19 2024-01-09 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
US12030936B2 (en) 2019-05-03 2024-07-09 Bioniz Therapeutics, Inc. Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2023064469A1 (en) * 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
WO2024036145A1 (en) * 2022-08-07 2024-02-15 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
AU720201B2 (en) 1995-03-08 2000-05-25 Scripps Research Institute, The Antigen presenting system and methods for activation of T-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
EP1335938B1 (en) * 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
EP1718282A4 (en) 2004-01-15 2010-07-14 Sinai School Medicine PROCESS AND COMPOSITIONS FOR IMAGE PRESENTATION
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008007146A1 (en) 2006-07-13 2008-01-17 Upperton Limited Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos

Also Published As

Publication number Publication date
AU2010329805B2 (en) 2016-07-14
CN102753574A (zh) 2012-10-24
JP2013513377A (ja) 2013-04-22
BR112012013868A2 (pt) 2017-01-10
US20120244118A1 (en) 2012-09-27
RU2012129208A (ru) 2014-01-20
EP2511294A2 (en) 2012-10-17
WO2011070214A3 (es) 2011-08-04
CN102753574B (zh) 2015-05-20
EP2511294B1 (en) 2014-02-26
US8771664B2 (en) 2014-07-08
WO2011070214A8 (es) 2011-09-29
WO2011070214A2 (es) 2011-06-16
ES2463016T3 (es) 2014-05-27
AU2010329805A1 (en) 2012-07-05
JP5784626B2 (ja) 2015-09-24
RU2597989C2 (ru) 2016-09-20
MX2012006691A (es) 2013-02-26
CA2783876A1 (en) 2011-06-16
BR112012013868A8 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
CA2783876C (en) New conjugates and compositions for immunotherapy and antitumoral treatment
EP3307783B1 (en) Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
US20250066442A1 (en) Fusion molecules and il-15 variants
US20200283498A1 (en) T cell receptor fusions and conjugates and methods of use thereof
MX2010012746A (es) Molecula adaptadora para la administracion de vectores de adenovirus.
US20210008167A1 (en) T cell receptor fusions and conjugates and methods of use thereof
ES2362062A1 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151126

MKLA Lapsed

Effective date: 20201210